To evaluate safety of a test product for skin irritatio

Not Applicable

Completed

• Registration Number: CTRI/2022/06/043046
• Lead Sponsor: Cipla Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-06-25
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 52

Inclusion Criteria

1.Voluntary men and women between 18 and 60 years.

2.Photo type III to V.

Having apparently healthy skin on test area.

3.For whom the Investigator considers that the compliance will be correct.

4. Cooperating, informed of the need and duration of the examinations, and ready to comply

with protocol procedures.

5.Having signed a Consent Form.

6. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the

course of the study.

7. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.:

exercise, saunaâ?¦), during the course of the study.

8 Should be able to read and write (in English, Hindi or local language).

9. Having valid proof of identity and age.

Exclusion Criteria

1. Pregnancy (by history) and lactating women.

2. Scars, excessive terminal hair or tattoo on the studied area.

3. Dermatological infection/pathology on the level of studied area.

4.Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).

5.Any clinically significant systemic or cutaneous disease, which may interfere with study

procedures.

6. Chronic illness which may influence the outcome of the study.

7. Participants on any medical treatment either systemic or topical which may interfere with

the performance of the study (presently or in the past 1 month).

8. Participant in an exclusion period or participating in another food, cosmetic or therapeutic trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of skin irritation reactions (erythema, oedema, dryness, scaling wrinkling), using Draize scale.Timepoint: Induction Phase: <br/ ><br>- Patch application on Visit V1, V3, V5, V7, V9, V11, V13, V15 and V17. <br/ ><br>- Patch removal on Visit 2 (V2, V4, V6, V8, V10, V12, V14, V16 and V18). <br/ ><br>- Scoring on Visit 3 (V3, V5, V7, V9, V11, V13, V15, V17, V19) <br/ ><br>Rest Phase: 10 â?? 14 days <br/ ><br>Challenge Phase: Patch application will be on naïve sites on the arm/back on V20; patch will be removed at V21 (24 hours). Scoring on V22 (48 hours), V23 (72 hours). V24 (96 hours). <br/ ><br> <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
oneTimepoint: None